Researcher aims to decode the epigenetic factors in pancreatic cancer and muscle wasting.
- Grant awarded for groundbreaking research in pancreatic cancer
- Study focuses on the epigenetic mechanisms involved in muscle wasting
- Researcher aims to unlock new treatment strategies
The National Cancer Institute has awarded a grant to Dr. Kelsey N. Kauffman from Rosalind Franklin University to study the epigenetic code associated with pancreatic cancer and its link to muscle wasting. This research aims to deepen understanding of how epigenetics influences cancer progression and the adverse effects it can have on patient health.
Dr. Kauffman's work will investigate how changes in gene expression due to epigenetic modifications may contribute to the debilitating symptoms often seen in pancreatic cancer patients. The study intends to explore new treatment strategies that could potentially mitigate muscle wasting, thereby improving quality of life for individuals affected by this aggressive form of cancer.
This funding represents a significant step forward in cancer research, particularly concerning conditions like pancreatic cancer that are notoriously difficult to treat. By focusing on the intricate relationship between epigenetics and muscle wasting, Dr. Kauffman's research could pave the way for innovative approaches to treatment.
